key: cord-0859798-riwojb40 authors: Espi, M.; Charmetant, X.; Barba, T.; Pelletier, C.; Koppe, L.; Chalencon, E.; Kalbacher, E.; Mathias, V.; Ovize, A.; Cart-Tanneur, E.; Bouze, C.; Pellegrina, L.; Morelon, E.; Juillard, L.; Fouque, D.; Couchoud, C.; Thaunat, O. title: Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study date: 2021-07-06 journal: nan DOI: 10.1101/2021.07.02.21259913 sha: a31302bd20618926152d51b2f274434bebdd8906 doc_id: 859798 cord_uid: riwojb40 Background: Patients on maintenance hemodialysis (MHD) are at high risk of infection with SARS-Cov-2 and death due to COVID-19. This vulnerable population has been prioritized for vaccination, but the level of protection achieved in these immunocompromised patients is unclear. Objectives: To evaluate the protection of MHD patients against COVID-19 after 2 doses (2D) of BNT162b2, and the safety and impact on immune responses of a 3rd dose (3D). Design: Prospective observational. Setting, Patients, intervention and measurements: REIN national registry was used to compare the severity of 1474 cases of COVID-19 diagnosed in MHD patients after 0, 1 or 2 doses of mRNA vaccine. Anti-spike receptor binding domain (RBD) IgG and interferon gamma-producing CD4+ and CD8+ specific-T cells were measured after 2D and 3D of BNT162b2 in a monocentric cohort of 75 MHD patients. Results: Vaccination reduced disease severity but 11% of MHD patients infected after 2D still died. Tolerance to 3D of BNT162b2 was excellent. MHD patients with humoral response similar to healthy volunteers after 2D did not generate more immune effectors after 3D and had more side effects. In contrast, 2/3 of MHD patients with suboptimal response after 2D reached optimal titer of anti-RBD IgG and/or developed spike-specific CD8+ T cells after 3D. Presence of spike-specific CD4+ T cells after 2D was associated with response to 3D in multivariate analysis (OR=4.80 [1.23-21.54]; p=0.029). Limitations: Limited number of patients injected with 3D. Conclusion: Standard scheme of vaccination provides insufficient protection to some MHD patients. Anti-RBD IgG and specific CD4+ T cells should be measured after 2D. Among patients with suboptimal humoral response, those with specific CD4+ T cells could benefit of a 3rd dose of vaccine. Background: Patients on maintenance hemodialysis (MHD) are at high risk of infection with SARS-Cov-2 and death due to COVID-19. This vulnerable population has been prioritized for vaccination, but the level of protection achieved in these immunocompromised patients is unclear. Results: Vaccination reduced disease severity but 11% of MHD patients infected after 2D still died. Tolerance to 3D of BNT162b2 was excellent. MHD patients with humoral response similar to healthy volunteers after 2D did not generate more immune effectors after 3D and had more side effects. In contrast, 2/3 of MHD patients with suboptimal response after 2D reached optimal titer of anti-RBD IgG and/or developed spike-specific CD8+ T cells after 3D. Presence of spike-specific CD4+ T cells after 2D was associated with response to 3D in multivariate analysis (OR=4.80 [1.23−21 .54]; p=0.029). Limitations: Limited number of patients injected with 3D. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint Introduction Among the various alarms raised by the COVID-19 pandemic was its impact on the population of patient with end stage renal disease (1, 2) , particularly those requiring in center hemodialysis. The logistical aspects of the technique indeed increase the risk of SARS-Cov-2 infections (3) , which on the highly co-morbid profile of MHD patients then translates into a high rate of COVID-19-related death (1, (4) (5) (6) . Aiming at protecting this vulnerable population, French health authorities prioritized MHD patients for vaccination (7) . However, while two doses (2D) administered intramuscularly three weeks apart of BNT162b2, a lipid nanoparticle-encapsulated mRNA-based vaccine, induced both strong humoral and cellular immune responses against the spike protein of SARS-CoV-2 in the general population (8) , our group (9) and others (10) (11) (12) (13) (14) have recently reported that MHD patients, particularly those that were naïve for SARS-Cov-2 virus, generated weaker responses as compared with healthy volunteers after this "standard" scheme of vaccination, raising question about their actual level of protection. The prospective observational ROMANOV-II (Response Of heModialyzed pAtieNts to cOvid-19 Vaccination) study, aimed at comparing the severity of COVID-19 disease in MHD patients according to their vaccination status, and at evaluating whether a 3 rd dose (3D) of BNT162b2 vaccine was safe and efficient to increase the generation of immune effectors. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint The Renal Epidemiology and Information Network (REIN) is the French national registry of all patients being treated by renal replacement therapy (15) . Clinical, demographic, and laboratory data are collected at the start of renal replacement therapy along with dialysis modalities and are updated annually. Events such as death, transfer, withdrawal from dialysis, placement on a transplant waiting list, and kidney transplantation (from living or deceased donors), as well as COVID-19 diagnosis and severity are systematically reported in real time. Interrogation of REIN registry was made on June 18 th , 2021 on the period from the February 1 st to May 18 th , 2021. Severity of COVID-19 was graded as asymptomatic, mild, moderate, severe, critical or death following the WHO recommendations (16) . Because protection of a vaccine dose was previously reported to be efficient from the tenth day following injection onward (17) , patients were considered as not vaccinated if COVID-19 infection was diagnosed within 10 days after the first dose, and as patients of the "after 1 dose" group if the diagnosis was made within 10 days after the second dose. According to the French health authority (18), a third vaccine injection with of mRNA BNT162b2 COVID-19 vaccine was offered to all patients on MHD in the two centers of Lyon University Hospital (France) that received two doses of mRNA BNT162b2 and that did not have any of the following contra-indications: diagnosis of COVID-19 within the last 3 months, organ transplantation within the last 3 months, Rituximab injection All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint within the last 3 months, ongoing flare of vasculitis, acute sepsis, major surgery within the last 2 weeks. Before the third injection, patients were informed of their serological status after two doses. All adult patients who received a third vaccine injection (within 3 months after the second vaccine injection) with BNT162b2 vaccine and gave consent for the use of their blood were enrolled in this study. The samples were collected 10 to 14 days after the 2 nd and after the 3 rd vaccine injection for analysis of the post-vaccinal immune response. This timing was selected based on previous reports demonstrating that both cellular and antibody responses are at their peak at this time point (8) . Post-vaccinal immune responses of MHD patients were compared after 2D and 3D to those of a cohort of healthy volunteers (HV), with blood collection at the same time point after the 2D of BNT162b2, used as a reference. This study was conducted in accordance with the French legislation on biomedical research and the Declaration of Helsinki, and the protocol was evaluated by a national ethical research committee (ID-RCB 2021-A00325-36) and registered on clinicaltrial.gov as NCT04881396. The French national commission for the protection of digital information (CNIL) authorized the conduction of the study. Local and systemic adverse events and use of anti-pyretic medications were collected retrospectively, based on a self-assessment questionnaire. Data collected correspond to adverse events within 7 days after the 2D and 3D, respectively. As previously described (17) , pain at the injection site was assessed according to the following scale: mild, does not interfere with activity; moderate, interferes with activity; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Briefly, 10µL of serum were incubated in the appropriate buffer with magnetic microbeads covered with S-RBD recombinant antigen, in order to form immune complexes. After precipitation in a magnetic field and washing, ABEI (N-(4-Aminobutyl)-N-ethylisoluminol)-stained anti-human IgG antibodies were added to the samples. After a second magnetic separation and washing, the appropriate reagents All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint were added to initiate a chemiluminescence reaction. When necessary, sera were diluted sequentially up to 1:1000. As recommended by the WHO (19) , the obtained titer was then expressed as binding arbitrary units/mL (BAU/mL). Spike specific CD4+ and CD8+ T cells responses were quantified in the circulation of the HV and HD patients using the QuantiFERON® SARS-CoV2 test (Qiagen, Netherlands), a commercially available Interferon Gamma Releasing Assay (IGRA), according to the manufacturer's instructions. Briefly, 1mL blood was distributed in each tube of the assay: (i) uncoated tube: negative control/background noise, (ii) tube coated with mitogen: positive control, (iii) tube coated with HLA-II restricted 13-mers peptides derived from the entire SARS-CoV2 Spike glycoprotein used to stimulate CD4+ T cells and (iv) tube coated with HLA-II and HLA-I 8-and 13-mers derived from the entire SARS-CoV2 spike glycoprotein used to stimulate both CD4+ and CD8+ T cells. After 20 hours of culture at 37°C, tubes were centrifugated 15 minutes at 2500g, and stored at 4°C before INFᵧ quantification in the supernatant by ELISA. The CD4+ T cell assay value was the difference between tube (iii) and the negative control (i). The CD8+ T cell assay value was the value obtained for tube (iv), with subtraction of the CD4 tube (iii) and the negative control (i). All the analyses were carried out using R software version 4.0.4 (R Foundation for Statistical Computing, Vienna, Austria, 2021, https://www.R-project.org) and or All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. GraphPad Prism v8.0 (San Diego, California USA). Categorical variables were expressed as percentages and compared with the chi-squared test. Continuous variables were expressed as mean ± SD and compared using one-way ANOVA and multiple t-tests post-hoc analyses or as median ± IQR and compared using Mann Whitney test for variables with non-normal distribution. Logistic regression models were used in both univariate and multivariate analyses. All the explanatory variables significantly associated with outcomes in univariate analyses (p-value < 0.10) were included in multivariate models. Stepwise regression analyses with bidirectional elimination were then performed, using Aikake Information Criterion to select the most fitting final multivariate models. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. Table 1 . Patients' characteristics were similar in the 3 groups with exception of age, cardiopathy and time in MHD, which were all three higher in patients who developed COVID-19 after 2D of vaccine, likely because the latter were vaccinated with the highest priority ( Table 1) . (17), and demonstrates that All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint vaccination with the 2D "standard" scheme is insufficient to protect all MHD patients. Figure 4A ) was therefore taken as reference and response to vaccine of MHD patients was considered optimal (n=40/106, 37.7%) or sub-optimal (n=66/106, 62.3%) depending whether the titer of anti-RBD IgG was respectively superior or equal, or inferior to this value ( Figure 2) . Table 2 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. When local and systemic side effects of vaccine were compared between 2D and 3D, no significant difference was found, neither regarding the frequency nor severity of symptoms ( Figure 3A-B) . However, when the profile of tolerance was compared between MHD patients according to the intensity of the humoral response after 2D of vaccine, a significant trend for more side effects was observed in patients with optimal response ( Figure 3C-D) . MHD patients with optimal humoral response after 2D of vaccine (n=19), all maintained high levels of anti-RBD IgG after 3D but without significant increase of their titer (2724 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. p=0.087; Figure 4B ). The remaining 56 MHD patients with suboptimal humoral response after 2D were distributed into two categories: i) those with anti-RBD IgG titer below the threshold of positivity of the assay (dotted line Figure 4A Figure 4D ), while the rest (5/12, 42%; Figure 4D ) did develop anti-RBD IgG but at suboptimal titers. Spike-specific T cell responses are also important components of the immune protection offered by the vaccine against SARS-Cov-2 (22) . T cell responses of MHD patients after 2D of vaccine was much more heterogeneous than that of HV ( Figure 4E & Figure 4I ). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint considered ( Figure 4E ). The result remained unchanged when the analysis was made within the subpopulations of MHD patients with optimal, low and no humoral response after 2D of vaccine ( Figure 4F-H) . Figure 4I ). Interestingly, the stronger effect was observed in the subpopulation of MHD patients with no-response after 2D of vaccine, the proportion with detectable spike-specific CD8+ T cells of which increases from 17% to 50% between 2D and 3D (p=0.09; Figure 4J -L) Because it was less well tolerated in these patients ( Figures 3C-D) and did not improve their immune response (Figures 4B, 4F , and 4J), we concluded that the subpopulation of MHD patients with already optimal humoral response after 2D should not receive a 3D of vaccine. In order to identify among the MHD patients with suboptimal response after the standard scheme of vaccination those who would benefit from 3D of vaccine, the characteristics of the MHD patients, who reached optimal titer of anti-RBD IgG and/or developed detectable levels of spike-specific CD8+ T cells after 3D (responders to 3D; n=35/56; 62.5%) were compared to that of the rest of the cohort (non-responders to 3D; n=21/56; 37.5%). The former group was younger and had developed higher titers of anti-RBD IgG and more spike-specific CD4+ T cells after 2D of vaccine ( Table 3) . In multivariate analysis, the only variable that predicted an immune response to 3D All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. Although, the safety of the 3D of BNT162b2 vaccine was excellent and comparable to that of the 2D with no critical local or systemic side-effect reported, the tolerance was worst in patients with already optimal humoral response, who did not improve significantly their immune response against the spike protein of SARS-Cov-2 after this additional injection. In contrast, after a 3D, 2/3 of MHD patients with suboptimal response after 2D, experienced an increase of anti-RBD-IgG titer up to optimal level and/or the appearance of spike-specific CD8+ T cells. This latter subgroup could be identified by the fact that they had developed spike-specific CD4+ T cells after 2D, a subset known to have crucial helper functions for the development of both antibodies (26) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint Based on the findings presented above, we propose the following strategy to optimize the protection of MHD patients naïve for SARS-Cov-2. All these vulnerable patients should be offered the standard scheme of vaccination in priority. Anti-RBD IgG and spike-specific CD4+ T cells should be measured in their circulation 10 to 14 days after 2D, resulting in the definition of 3 subgroups with distinct needs : i) patients with optimal anti-RBD IgG titer do not require further intervention, ii) patients with suboptimal anti-RBD IgG titer but detectable spike-specific CD4+ T cells, whom are the most likely to respond, should be offered a 3D of vaccine, and iii) patients with suboptimal anti-RBD IgG titer but no detectable spike-specific CD4+ T cells after 2 doses, in which the 3D of vaccine is unlikely to be sufficient, might rather be listed to receive infusion of monoclonal antibodies as a mean to induce passive immunization. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint All authors declared no conflicts of interest. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint Tables Table 1 -Characteristic of COVID-19 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint Table 3 -Uni and multivariate analysis used to identify predictors of an immunological response (i.e optimal humoral response or apparition of CD8+ response) after the 3 rd dose). Abbreviations are: Non-Resp, patients without optimal humoral response after the 3 rd dose neither apparition of CD8+ response; Resp, patients with optimal humoral response or apparition of CD8+ response; BMI, body mass index; OR, odd ratio; CI95%, 95% confident interval; SOT, solid organ transplantation; IS, immunosuppressive; HD, hemodialysis; Kt/V was used for the quantification of dialysis adequacy by the formula: dialysis clearance of urea (K) multiplied by t (dialysis time) divided by the volume of distribution of urea (V); CRP, c reactive protein. The number and the severity of local and systemic adverse events that occurred after 3D of vaccine were compared between Opt and S-Opt patients. Chi square test. Abbreviations are: ns, p non-significant; ***, p<0.0001. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. Evolution of anti RBD-IgG titers between the 2D and 3D of vaccine were compared in optimal responders (n=19, 4B), low responders (n=44, 4C) and non-responders (n=12, 4D). Wilcoxon test. E-H/ Secretion of interferon gamma by circulating spike-specific CD4+ T cells (4E). The proportion of MD patients with spike-specific CD4+ T cells were compared between the 2D and 3D of vaccine for optimal-(4F), low-(4G), and non-responders (4H). Chi square test. I-L/ Secretion of interferon gamma by circulating spike-specific CD8+ T cells (4I). The proportion of MD patients with spike-specific CD8+ T cells were compared between the 2D and 3D of vaccine for optimal-(4F), low-(4G), and non-responders (4H). Chi square test. Abbreviations are: ns, p non-significant; ****, p<0.0001. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint Figure 1 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint Figure 2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint Figure 3 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint Figure 4 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.02.21259913 doi: medRxiv preprint IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT) Factors associated with COVID-19-related death using OpenSAFELY Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology Outcomes of patients with end-stage kidney disease hospitalized with COVID-19 Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration Vaccins Covid-19 : quelle stratégie de priorisation à l'initiation de la campagne ? COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses Impaired humoral and cellular immune responses to SARS-Cov-2 mRNA vaccine in naïve maintenance hemodialysis patients: the ROMANOV study Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients 2021040480. and Kidney Transplant Recipients Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2 Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France Clinical management: living guidance Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody Réseau Epidémiologique et Information en (…) -Agence de la biomédecine COVID-19 Treatment Guidelines T cell responses in patients with COVID-19 Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells Immune cell dysfunction and inflammation in end-stage renal disease A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression The authors are indebted to the members of the GRoupe de REcherche Clinique